These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Lahaye T, Riehm B, Berger U, Paschka P, Müller MC, Kreil S, Merx K, Schwindel U, Schoch C, Hehlmann R, Hochhaus A. Cancer; 2005 Apr 15; 103(8):1659-69. PubMed ID: 15747376 [Abstract] [Full Text] [Related]
46. Lymphoid transformation in a CML patient in complete cytogenetic remission following treatment with imatinib. Avery S, Nadal E, Marin D, Olavarria E, Kaeda J, Vulliamy T, Brito Babapulle F, Goldman JM, Apperley JF. Leuk Res; 2004 May 15; 28 Suppl 1():S75-7. PubMed ID: 15036946 [Abstract] [Full Text] [Related]
47. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. O'Brien S, Giles F, Talpaz M, Cortes J, Rios MB, Shan J, Thomas D, Andreeff M, Kornblau S, Faderl S, Garcia-Manero G, White K, Mallard S, Freireich E, Kantarjian HM. Cancer; 2003 Sep 01; 98(5):888-93. PubMed ID: 12942553 [Abstract] [Full Text] [Related]
48. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia. Kim DH, Popradi G, Sriharsha L, Kamel-Reid S, Chang H, Messner HA, Lipton JH. Cancer; 2008 Aug 15; 113(4):772-81. PubMed ID: 18543309 [Abstract] [Full Text] [Related]
53. Imatinib-associated neutropenia may not be overcome by filgrastim treatment in patients with blastic phase of chronic myeloid leukaemia. Zaucha JM, Wyrowinska E, Prejzner W, Calbecka M, Hellmann A. Clin Lab Haematol; 2006 Jun 15; 28(3):208-10. PubMed ID: 16706939 [Abstract] [Full Text] [Related]
56. A 51-year-old male CML patient with progressive hearing loss, confusion, ataxia, and aphasia during imatinib treatment. Janssen JJ, Berendse HW, Schuurhuis GJ, Merle PA, Ossenkoppele GJ. Am J Hematol; 2009 Oct 15; 84(10):679-82. PubMed ID: 19658186 [No Abstract] [Full Text] [Related]
57. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase. Kantarjian H, O'Brien S, Cortes J, Shan J, Giles F, Garcia-Manero G, Verstovsek S, Faderl S, Rios MB, Talpaz M. Cancer; 2003 Oct 01; 98(7):1430-7. PubMed ID: 14508830 [Abstract] [Full Text] [Related]
58. [Reversion to chronic phase of chronic myelogenous leukemia in blast crisis with small-dose daunorubicin and oral prednisolone]. Kuyama J, Take H. Rinsho Ketsueki; 1995 Dec 01; 36(12):1353-8. PubMed ID: 8587171 [Abstract] [Full Text] [Related]